Last reviewed · How we verify
NCT00958698
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NA trial testing Communication Intervention in Fallopian Tube Carcinoma in 485 participants. Status unknown.
8 January 2017
Quick facts
| Lead sponsor | Gynecologic Oncology Group |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 485 |
| Start date | 19 January 2010 |
| Primary completion | 8 January 2017 |
| Sites | 144 locations across United States |
Drugs / interventions tested
- Communication Intervention
- Educational Intervention
- Internet-Based Intervention
- Psychosocial Assessment and Care
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Fallopian Tube Carcinoma — all drugs for Fallopian Tube Carcinoma →
- Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →
- Psychological Impact of Cancer — all drugs for Psychological Impact of Cancer →
- Recurrent Ovarian Carcinoma — all drugs for Recurrent Ovarian Carcinoma →
Sponsor
Gynecologic Oncology Group — full company profile →
Who can join
18 and older, female only, with Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized clinical trial is studying two different symptom management programs to see how well they work compared with usual care in patients with recurrent or persistent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Developing a symptom management plan may help relieve symptoms related to cancer or cancer treatment and help improve quality of life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
Donovan HS, Sereika SM, Wenzel LB, Edwards RP, et al · · 2022 · cited 14× · PMID 35130043 · DOI 10.1200/jco.21.00656
Verify or expand the search:
- PubMed search for NCT00958698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Communication Intervention
Trials testing the same drug.
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT04871477 — Adoption of Audio Recording in the Outpatient Supportive Care Center · not yet recruiting
- NCT07143487 — Family Communications After Genetic Testing · NA · not yet recruiting
- NCT07186530 — Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening · NA · enrolling by invitation
Other recruiting trials for Fallopian Tube Carcinoma
Currently open trials in the same condition.
- NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06710548 — REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors · NA · recruiting
- NCT06492070 — Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecolo · Phase 2 · recruiting
- NCT06420973 — RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression · Phase 2 · recruiting
Other Gynecologic Oncology Group trials
Trials by the same sponsor.
- NCT04393285 — Abemaciclib and Letrozole to Treat Endometrial Cancer · Phase 2 · active not recruiting
- NCT03673124 — Ribociclib and Letrozole Treatment in Ovarian Cancer · Phase 2 · active not recruiting
- NCT02065687 — Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent · Phase 2, PHASE3 · unknown
- NCT01720173 — Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Phase 2 · completed
- NCT01406769 — Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stag · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00958698 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gynecologic Oncology Group
- Last refreshed: 12 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00958698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing